ArticleRheumatology international2011
Churg-Strauss syndrome successfully treated with rituximab.
Article in Rheumatology international, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 56 citations in OpenAlex.
- Rituximab for the treatment of Churg-Strauss syndrome with renal involvement.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2011Trial
- Review
- Unmet Needs in the Pathogenesis and Treatment of Vasculitides.Clinical reviews in allergy & immunology · 2018Review
- Successful use of Rituximab in a patient with recalcitrant multisystemic eosinophilic granulomatosis with polyangiitis.BMJ case reports · 2015Article
- Experience with rituximab in the treatment of antineutrophil cytoplasmic antibody associated vasculitis.Therapeutic advances in musculoskeletal disease · 2014Review
- Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).Arthritis research & therapy · 2013Article
- B-lymphocyte lineage cells and the respiratory system.The Journal of allergy and clinical immunology · 2013Review
- Churg-strauss syndrome with eosinophilic myocarditis: a clinical pathology conference held by the division of rheumatology at hospital for special surgery.HSS journal : the musculoskeletal journal of Hospital for Special Surgery · 2012Article
- Emerging trends in the formation and function of tuberculosis granulomas.Frontiers in immunology · 2012Article
- Rituximab ameliorated severe hearing loss in Cogan's syndrome: a case report.Orphanet journal of rare diseases · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Churg-Strauss syndrome (CSS) is characterized by small-vessel vasculitis, extravascular granulomatous inflammation, and massive eosinophilia in tissues and blood, and is often accompanied by a history of preclinical asthma and/or allergic rhinitis lasting several years before the syndrome develops its full clinical picture. Corticosteroids, often in combination with cytotoxic agents, comprise standard therapy; however, a number of patients appear to be resistant to treatment and there is a need for more effective regimens. B cell depletion may be an effective treatment option for CSS. Here, we describe two patients resistant to conventional therapy who were treated with rituximab and experienced a rapid and substantial decrease in disease activity and asthmatic symptoms and an increase in physical capacity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.